Thirteen Indians on Forbes 100 Best Venture Capitalists

Salil Deshpande, Ravi Mhatre & Promod Haque on Forbes list of 100 Best Venture Capitalists in 2017


Indians on the Forbes 100 Best Venture Capitalists list for 2017 include Salil Deshpande of Bain Capital Ventures, Ravi Mhatre of Lightspeed Ventures, Promod Haque of Norwest Venture Partners 


Others on the list include:



Asheem Chandna
Greylock Partners


"Asheem Chandna is on a hot streak as the enterprise software guru at top venture firm Greylock. The investor co-led the Series A in AppDynamics in 2008 on behalf of the firm; in January of 2017, Cisco swooped in to acquire the app performance management company shortly before it was set to go public for $3.7 billion....... Born in India, Asheem Chandna joined Greylock in 2003 after serving as vice president of business development and product management at Check Point Software..... When not at Greylock, Asheem can be found hiking and running around Stanford University's campus...."


Hemant Taneja
Managing Director, General Catalyst Partners

"Hemant Taneja debuts on the Midas List due to an early investment in Snap, the social platform that went public at a market capitalization of $25 billion in February 2017..........Along with Color, which offers genetic testing for common cancers, some of Taneja's newest bets include drone data company Airmap and search analytics company Thoughtspot. The one-time competitive Bhangra dancer is a board member at education non-profit Khan Academy and holds five degrees from MIT."


For more on the Indians on the list go Forbes 100 Best Venture Capitalists 2017













Comments

Post a Comment

Popular posts from this blog

Satish Mehta CEO of Emcure Pharmaceuticals and a Drug Price-Fixing Scandal

The Billionaire And The Drug Price-Fixing Scandal. Forbes article Satish Mehta founded Emcure Pharmaceuticals in 1981. In 2011 Emcure bought U.S. based Heritage Pharmaceuticals founded by Jeffrey Glazer. In 2016 Heritage had U.S. sales of $265 million, 40% of Emcure's total sales. An article in Forbes , by Nathan Vardi and Nazneen Karmali April 25, 2017, says that, " In September 2015, Satish Mehta, the billionaire chief executive of the Indian drug company Emcure Pharmaceuticals, wrote an effusive email congratulating Jeffrey Glazer, the CEO of his U.S. crown jewel, Heritage Pharmaceuticals, on a job well done. "In a short span of 4.5 years, you have taken Heritage to another level," Mehta wrote, adding that he considered Glazer to be "an integral part of our family." In January this year, the article continues, "Glazer pleaded guilty to violating U.S. antitrust law by conspiring with manufacturers to fix the prices of generic drugs. Glazer is
Read more

Why Second Generation Indians in U.S. will not be as Successful:

Image
The Bamboo Ceiling for Asians at U.S. Colleges Extract from "Six Degrees of Education: From Teaching in Mumbai to Investment Research in New York" by Ignatius Chithelen  Published by India Today Online August 3, 2016  Why Second Generation Indians in the U.S. will not be as Successful S ince the 1980s, several million Indians have studied at U.S. colleges. Over a million have stayed on in the U.S. through employment visas and many of them have become successful as professionals and some as entrepreneurs. They include chief executives of major U.S. companies such as Sundar Pichai at Google, Satya Nadella at Microsoft, Shantanu Narayen at software vendor Adobe, Indra Nooyi at Pepsico and Rakesh Sachdev of chemicals and bio-chemicals supplier Sigma-Aldrich. Businesses founded or co-founded by Indians in the U.S. include Cascade Communications, Daisy Systems, Epitome, Hotmail, Junglee, Morphotek, Solar Junction and TIBCO Software.  Some Indian en
Read more